10x Genomics has announced they and PerkinElmer, Inc. will jointly offer automated next-generation sequencing (NGS) solutions. PerkinElmer’s automation solutions increase both the throughput and efficiency of assays, while also allowing researchers to streamline and enhance existing NGS workflows.
“Our collaboration with PerkinElmer underscores 10x’s commitment to advancing the way we look at and understand genetic information,” said Serge Saxonov, co-founder and chief executive officer of 10x Genomics. “As genomic research becomes more and more prominent, access to 10x solutions will illuminate a more comprehensive understanding of disease. By offering the Chromium™ System together with high-throughput automation platforms from PerkinElmer, we believe we will not only better serve our customers, we will also create a compelling workflow for meeting the research community’s critical need for long range, structural and cellular information.”
The 10x Genomics Chromium System features proprietary Linked-Read sequencing technology which only requires small fragments of DNA (approximately 1ng) to deliver long-range sequence information, perform haplotype phasing and reveal structural genomic variation, as well as other genomic content. When combined with PerkinElmer® automated solutions, the 10x Genomics Chromium System can significantly increase the throughput of existing sequencing workflows.
PerkinElmer continues to work with industry leaders to develop simple, sequence-verified automation protocols, including 10x Genomics’ Linked-Read technology. These protocols will provide researchers novel options for automated genome, exome and single-cell assay library preparation, enabling the increased throughput and efficiency required to meet the growing needs of today’s life science research community.
“This relationship with 10x Genomics will enhance the PerkinElmer automation menu and help progress researchers’ interpretation of some of the most important biological questions through increased sequence information and insights into the complexity of the genome,” said Prahlad Singh, Senior Vice President and President, Diagnostics, PerkinElmer. “The combination of 10x Genomics’ advanced technology and the precision automation provided by PerkinElmer’s portfolio will potentially enable a significant increase in sample numbers and elucidate important genomic variants that are associated with specific phenotypic traits or the progression of disease.”
Please note: The content above may have been edited to ensure it is in keeping with Technology Networks’ style and length guidelines.